Regeneron Pharmaceuticals Inc
Related Articles
Regeneron Is Down despite Earnings Beat
Regeneron (REGN) reported its Q2 earnings results before the markets opened. REGN reported revenues of $1.93 billion, a YoY increase of 20%.
Sanofi’s Immunology Portfolio in the First Quarter
In the first quarter, Sanofi’s (SNY) Immunology Franchise reported net sales of 359 million euros.
Analyzing Sanofi’s Oncology Portfolio in the First Quarter
In the first quarter, Sanofi’s (SNY) Oncology franchise reported net sales of 399 million euros, a YoY rise of 7.8% on a CER (constant exchange rate) basis.
Analysts Raise Their Target Price for Regeneron in March
Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.
What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.
Assessing BeiGene Limited’s Gross Margin Trend
In the third quarter, BeiGene’s (BGNE) total revenue fell YoY (year-over-year) to $54.2 million from $220.21 million.
Do Analysts See Any Upside for Sarepta Stock?
Of the 23 analysts covering Sarepta Therapeutics (SRPT), 22 have given it “buy” or higher ratings, and one has given it a “hold.”
Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Analyzing Sarepta Therapeutics’ Gross Margin Trends
In the third quarter, Sarepta’s cost of sales excluding the amortization of in-licensed rights rose YoY (year-over-year) to $8.74 million.
Taking Stock of Sarepta’s Latest Performance
In the third quarter, Sarepta’s total revenue rose year-over-year to $78.49 million due to increasing demand for its drug Exondys 51.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
Do Analysts See Any Upside for Regeneron Stock?
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”
What Regeneron Pharmaceuticals’ Bottom Line Indicates
In this year’s third quarter, Regeneron Pharmaceuticals’ (REGN) interest expenses rose YoY (year-over-year) to $7.49 million from $6.18 million, and its net other income rose YoY to $16.43 million from $11.86 million.
Understanding Regeneron Pharmaceuticals’ Operational Performance
In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount.
Regeneron Pharmaceuticals’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.
Taking Stock of Regeneron’s Performance
In this series, we’ll explore Regeneron Pharmaceuticals’ (REGN) financials and valuation, and analysts’ views on its stock.
Austedo Is on Solid Growth Trajectory in 2018
In the third quarter, Austedo reported revenues of $62 million, which is a YoY rise of 933.33% and a sequential rise of 40.91%.
Jazz Pharmaceuticals: A Financial Overview in November
Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth.
Jazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.
How Wall Street Analysts View Alkermes after Q3 Earnings Release
On October 24, Alkermes (ALKS) stock closed at $40.03, which is 44% below its 52-week high of $71.22 on February 16.
Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
Regeneron and Alnylam Collaborate for NASH Research Program
Alnylam Pharmaceuticals (ALNY) is currently trading 1.47% higher than its 52-week low price of $78.85 and 48.04% lower than its 52-week high price of $153.99.
How Regeneron Stock Performed in the First Half of October
On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12.
Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.
Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.
Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.
Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.
Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.
Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.
Analyzing Regenxbio’s Valuation Metrics
Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.
Teva Stock Continues to Trend Higher on Positive News
Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.
Teva Pharmaceutical Stock in the Week Ended August 17
On August 16, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $24.11, a rise of ~7.3% compared to the previous day’s closing price.
Teva and Regeneron Announced Positive Top-Line Data on Fasinumab
On August 16, Teva Pharmaceutical Industries (TEVA) and Regeneron Pharmaceuticals (REGN) announced positive top-line results for Fasinumab.
FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.
Why Vertex Is Expected to Report Robust EPS Growth in 2018
Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.
Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth
In its Q2 2018 earnings conference call, Vertex updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion.
OPKO Health Expects Its Loss per Share to Shrink This Year
In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million.
OPKO Health’s Q3 2018 Revenue Expectations
In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes.
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.
What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
Analysts Are Mostly Positive on Neurocrine Biosciences in August
In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis.
How Neurocrine Biosciences Performed in the Second Quarter
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017.
Regeneron Stock Up 7% on Strong Q2 2018 Results
On August 2, Regeneron Pharmaceuticals (REGN) posted earnings results for its fiscal second quarter of 2018, which ended on June 30.
How United Therapeutics Fared in the Second Quarter of 2018
In the second quarter of 2018, United Therapeutics (UTHR) generated revenues of $444.5 million compared to $444.6 million in Q2 2017.
What to Expect from Regeneron’s Second-Quarter Earnings
Regeneron Pharmaceuticals (REGN) is slated to release its fiscal second-quarter results tomorrow before the market opens.
A Look at PTC Therapeutics’ Financial Position
PTC Therapeutics (PTCT) generated revenues of $56.1 million in Q1 2018, compared to $26.5 million in Q1 2017.
How Analysts View Exelixis ahead of Its Q2 2018 Results
In June, Exelixis (EXEL) announced that it would be added to the S&P MidCap 400 Index before the market opened on July 2.
How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release
Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.
Why Tonix Pharmaceuticals Stock Soared Today
Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.
Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.
A Review of Ionis’s Revenue Stream
As discussed earlier, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) in Q1 2018, and analysts expect it to grow 30.6% YoY to $136.0 million in Q2 2018.
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
Analysts Are Mostly Positive on Exelixis in July
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.
Analysts Are Mostly Feeling Good about Vertex Pharmaceuticals
In the week that ended on June 29, Vertex Pharmaceuticals (VRTX) stock closed at $169.96.
Pediatric Atopic Dermatitis Indication May Boost Dupixent Revenue
A label expansion could further advance Dupixent’s position in the atopic dermatitis market.
Dupixent May Be a Solid Growth Driver for Regeneron in 2018
In the first quarter, Regeneron (REGN) and Sanofi’s (SNY) Dupixent witnessed global sales of close to $131 million.
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.
Diabetic Eye Diseases May Prove a Strong Growth Driver for Eylea
Regeneron (REGN) is focused on advancing Eylea in the diabetic retinal disease segment.
Regeneron Is Expected to Witness a Modest Rise in Diluted EPS
Wall Street analysts expect Regeneron to report non-GAAP diluted EPS of close to $18.7 in 2018, a YoY rise of ~14.8%.
Regeneron Is Expected to Witness a Modest Revenue Rise in 2018
Regeneron (REGN) currently has six FDA-approved drugs and 17 investigational therapies in its research pipeline.
Analysts’ Recommendations for Regeneron and Its Peers in June
Of the 25 analysts covering Regeneron in June, four have recommended “strong buys” and four have recommended “buys” on the stock.
Solid Biosciences’ Stock Price Rose 46.6% on June 19
On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.
S&P 500’s Gainers: Assurant and CVS Closed Higher on June 19
Assurant, which is a global provider of risk management products and services, was the S&P 500’s top gainer on June 19.
The Economy Is on a Roll, and It’s Bringing the Stock Market Along With It
Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Insights into the Cash Flows and Valuations of Editas Medicine
Since the beginning of 2018, Editas Medicine’s (EDIT) share price has risen 5.1% to close at $36.06 on May 23.
How Clovis Oncology’s Cash Flow and Valuation Compare
In the first quarter, Clovis Oncology’s (CLVS) operating expenses rose YoY (year-over-year) to $100.6 million from $80.4 million, due to a larger net loss and inventories rising.
What’s Clovis Oncology’s Return Potential?
Clovis Oncology (CLVS) is a biopharmaceutical company with a focus on acquiring, developing, and commercializing anti-cancer agents.
Ionis Pharmaceuticals’ Valuation on May 23
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.
Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21.
Analyst Views on the Upside Potential of Alnylam Pharmaceuticals
Of the 16 analysts covering Alnylam Pharmaceuticals in May, 12 analysts have given the stock a “buy” or higher rating.
What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.
Analysts’ Recommendations for Regeneron Pharmaceuticals in May
Of the 25 analysts tracking Regeneron Pharmaceuticals in May, four have recommended “strong buys” on the stock.
How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?
In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17.
How Regeneron’s Praluent and Dupixent Performed in 1Q18
In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17.
How Did Regeneron Pharmaceuticals Perform in 1Q18?
Regeneron Pharmaceuticals (REGN) reported its 1Q18 earnings results on May 3. It generated revenue of $1.5 billion in the quarter.
Wall Street Recommendations for Exelixis in May 2018
In May 2018, Exelixis (EXEL) and Invenra, entered into a collaboration agreement for the innovation and development of multispecific antibodies for cancer treatment.
How Did Exelixis Perform in 1Q18?
In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.
How Repatha Is Positioned after 1Q18
In 1Q18, Amgen’s (AMGN) Repatha revenue grew 15% YoY (year-over-year) to $123 million from $49 million, primarily due to higher unit demand.
Analysts’ Recommendations for Vertex Pharmaceuticals
Of the 26 analysts tracking Vertex in April, ten have recommended “strong buy,” 12 have recommended “buy,” and four have recommended “hold.”
What Analysts Recommend for Neurocrine Biosciences in April 2018
Four analysts recommended a “strong buy” on Neurocrine Biosciences, while seven analysts recommended a “buy” rating.
How Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings
In 4Q17, Neurocrine Biosciences (NBIX) generated revenues of $94.5 million, which reflected ~56% growth on a quarter-over-quarter basis.
Analysts’ Recommendations for Exelixis in April 2018
In January 2018, Exelixis entered into an exclusive collaboration agreement with StemSynergy Therapeutics.
Upadacitinib Could Drive AbbVie’s Long-Term Growth
In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis.
Exploring the Growth of Regeneron’s Praluent
In April 2017, the FDA approved a supplemental biologics license application (or sBLA) for Praluent for a once-monthly dose.
Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.
Regeneron Pharmaceuticals’ Dupixent, Kevzara, and Zaltrap
In 4Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $139.0 million compared to $88.9 million in 3Q17.
A Post-4Q17 Update on Praluent’s Performance
In 4Q17, Regeneron Pharmaceuticals’ (REGN) Praluent generated revenues of $63.0 million, which reflected ~54.0% year-over-year growth.
How Regeneron Pharmaceuticals’ Eylea Performed in 4Q17 and 2017
In 4Q17, Eylea generated net global revenues of $1.6 billion compared to ~$1.4 billion in 4Q16.
How Regeneron Pharmaceuticals Performed in 4Q17 and Fiscal 2017
In fiscal 2017, Regeneron Pharmaceuticals generated revenues of ~$5.9 billion compared to ~$4.9 billion in 2016, which represents ~21.0% year-over-year growth.
Why Regeneron Pharmaceuticals’ Stock Price Fell
Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”
How Novartis’s Ophthalmology Business Performed in 2017
In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.
How Ionis’s Spinraza Performed in 4Q17
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is a drug designed for the treatment of spinal muscular atrophy.
How Did Ionis’s Revenues Trend in 4Q17?
Ionis (IONS) is a leading biopharmaceutical company focused on discovering, developing, and commercializing RNA-targeted therapies.